OGT’s unique UPD detection capability (patent pending) has been enabled by multiple rounds of SNP probe selection and validation, targeting over 6000 SNPs with evenly distributed probes, resulting in highly informative content that allows confident detection of whole chromosome UPD. Furthermore, the combined ISCA-UPD array has been developed to ensure near identical labelling and hybridisation conditions to standard aCGH. In addition, the aCGH protocol is largely unaltered and any reference DNA can be used. The latest version of OGT’s CytoSure Interpret Software provides simple and intuitive data analysis, with clear identification of regions with a loss of heterozygosity (LOH) and data processing tools to investigate these further. As a result of this unique array design and data analysis capability, segmental as well as whole chromosome UPD can be detected using the CytoSure ISCA UPD array.
James Clough, Vice President Clinical and Genomic Solutions at OGT commented: “We have carefully implemented robust UPD detection capabilities onto our CytoSure ISCA 4 x 180k arrays, whilst avoiding wholesale changes to the protocol. Importantly, we have also made the interpretation of this additional data extremely intuitive via our CytoSure Interpret Software. As a result, our customers can now confidently detect both DNA copy number variation and whole chromosomal uniparental disomy using a single array.”
OGT’s powerful CytoSure ISCA arrays have been carefully developed to focus on disease and syndrome-associated genome regions, in addition to offering whole genome coverage. Using a proprietary 60-mer probe design and multiple rounds of optimisation, the CytoSure ISCA aCGH arrays ensure exceptional reliability and confident detection of genetic aberrations with high signal-to-noise ratios.
For further information on OGT’s cytogenetics products and services please visit www.ogt.co.uk.
For further information, please contact: Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk W: www.ogt.co.uk
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
